<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006799</url>
  </required_header>
  <id_info>
    <org_study_id>REBACDR0000068329</org_study_id>
    <secondary_id>CCCWFU-97300</secondary_id>
    <secondary_id>CCCWFU-0009</secondary_id>
    <secondary_id>CCCWFU-BG00-228</secondary_id>
    <secondary_id>NCI-P00-0174</secondary_id>
    <nct_id>NCT00006799</nct_id>
  </id_info>
  <brief_title>Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in
      limiting weight loss caused by cancer.

      PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in limiting
      weight loss and improving quality of life in patients who have head and neck cancer and are
      undergoing radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the effect of megestrol on the weight of patients with head and neck cancer
           who are undergoing localized radiotherapy.

        -  Determine whether health-related quality of life improves in patients treated with
           megestrol.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to type of treatment (radiotherapy alone vs radiotherapy plus
      platinum-based chemotherapy vs radiotherapy plus non-platinum-based chemotherapy) and type of
      radiotherapy (primary vs postoperative). Patients are randomized to one of two treatment
      arms.

        -  Arm I: Patients receive oral megestrol daily beginning within the first three days of
           radiotherapy and continuing during 5-7 weeks of radiotherapy and for 12 weeks after
           completion of radiotherapy.

        -  Arm II: Patients receive oral placebo daily according to the schedule for megestrol in
           arm I.

      Quality of life is assessed at baseline, at completion of radiotherapy, and then at 4, 8, 12,
      and 16 weeks after completion of radiotherapy.

      PROJECTED ACCRUAL: A total of 48-144 patients (24-72 per arm) will be accrued for this study
      within 14 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2000</start_date>
  <completion_date type="Actual">September 6, 2002</completion_date>
  <primary_completion_date type="Actual">September 6, 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <enrollment type="Actual">13</enrollment>
  <condition>Anorexia</condition>
  <condition>Cachexia</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Quality of Life</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>megestrol acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven resected or unresectable stage I-IV epithelial head and neck
             cancer

          -  Must be scheduled to receive a total dose of radiotherapy of at least 5,000 cGy in
             fraction sizes of no greater than 200 cGy

          -  No distant metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  More than 3 months

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  No history of congestive heart failure or thromboembolic events

          -  No uncontrolled hypertension, active thromboembolic disease, or myocardial infarction
             within the past 3 months

        Pulmonary:

          -  No history of pulmonary edema

        Other:

          -  No other malignancy within the past 3 years except curatively treated carcinoma in
             situ of the cervix or nonmelanoma skin cancer

          -  No feeding tube

          -  No preexisting or uncontrolled diabetes with glycosylated hemoglobin greater than 10%

          -  No history of Cushing's syndrome

          -  No dietary restriction (salt, sugar, or lipid)

          -  No serious medical or psychiatric illness that would preclude study

          -  No significant ascites, pleural effusions, or edema that may inhibit oral food intake
             or invalidate weight measurements

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Prior chemotherapy allowed

        Endocrine therapy:

          -  At least 1 year since prior corticosteroids, estrogens, progestins, or any other
             steroid hormone

          -  No concurrent estrogens or other progestins

          -  Concurrent glucocorticoid replacement (10 mg of prednisone a day) allowed only if
             patient experiences moderate &quot;stress&quot; (e.g., infection, trauma, or fluid loss
             sufficient to require hospitalization and/or IV fluid replacement)

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to the head and neck

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn M. Greven, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>July 25, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2003</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I basal cell carcinoma of the lip</keyword>
  <keyword>stage I verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage I adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II basal cell carcinoma of the lip</keyword>
  <keyword>stage II verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage II mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage II adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>anorexia</keyword>
  <keyword>cachexia</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

